Market Overview

Insmed Shares Rally Over $14 As Piper Jaffray Boosts Price Target To $51

Related INSM
H.C. Wainwright: Time To Buy Insmed
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Shares of Insmed (NASDAQ: INSM) spiked nearly 5 percent higher in mid-day trade Wednesday afternoon following some bullish comments from Piper Jaffray's Dr. Joshua Schimmer. The stock is now up more than 3 percent to around $14.49.

Schimmer boosted his price target on Insmed shares by about 13 percent from $45 to $51. The analyst maintains an Overweight rating on Insmed.

Schimmer cited the company's overall long-term strategy and tax structure, as well as upcoming opportunities for Arikayce in the Japanese market. The Piper analyst is optimistic about Insmed's current initiative to explore avenues to shift intellectual property to a lower tax region.

Amid concerns a potentially brief Phase 3 trial will be needed in order to receive FDA approval for Arikayce in nontuberculous mycobacterial, Schimmer believes new opportunities for Insmed will more than offset conservative estimates.

Based on the price of Insmed shares Wednesday afternoon, Schimmer's new price target implies potential upside of a jaw-dropping 250 percent.

Latest Ratings for INSM

Feb 2015Janney CapitalInitiates Coverage onBuy
Sep 2014Cowen & CompanyInitiates Coverage onOutperform
May 2014WedbushTerminatesUnderperform

View More Analyst Ratings for INSM
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Analyst Ratings Movers


Related Articles (INSM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters